Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$5.34 - $11.09 $578,279 - $1.2 Million
-108,292 Reduced 36.84%
185,653 $1.98 Billion
Q4 2023

Feb 14, 2024

BUY
$5.26 - $11.04 $1.55 Million - $3.25 Million
293,945 New
293,945 $1.7 Billion

Others Institutions Holding GHRS

About GH Research PLC


  • Ticker GHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,020,800
  • Market Cap $348M
  • Description
  • GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH0...
More about GHRS
Track This Portfolio

Track Checkpoint Capital L.P. Portfolio

Follow Checkpoint Capital L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Checkpoint Capital L.P., based on Form 13F filings with the SEC.

News

Stay updated on Checkpoint Capital L.P. with notifications on news.